Crude lymphocyte levels: Can the past accelerate the future in preventive medicine?
作者信息
Zidar David A
机构信息
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Department of Medicine, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
出版信息
Am J Hematol. 2023 Dec;98(12):1826-1828. doi: 10.1002/ajh.27125. Epub 2023 Oct 14.
Abstract
摘要
相似文献
1
Crude lymphocyte levels: Can the past accelerate the future in preventive medicine?原始淋巴细胞水平：在预防医学中，过去能否加速未来？
Am J Hematol. 2023 Dec;98(12):1826-1828. doi: 10.1002/ajh.27125. Epub 2023 Oct 14.
2
[The past, present and future of preventive medicine].[预防医学的过去、现在与未来]
An R Acad Nac Med (Madr). 1960;77:195-215.
3
Past and future in preventive medicine.预防医学中的过去与未来。
N Z Med J. 1951 Apr;50(276):97-101.
4
5
"Social and preventive medicine"--past achievements and future challenges.“社会与预防医学”——过去的成就与未来的挑战。
Soz Praventivmed. 2005;50(6):339-40. doi: 10.1007/s00038-005-4091-5.
6
Separation of the gonadotropic activity of crude choriogonadotropin from the inhibitory effect on lymphocyte transformation.从对淋巴细胞转化的抑制作用中分离粗制绒毛膜促性腺激素的促性腺活性。
Hoppe Seylers Z Physiol Chem. 1979 Oct;360(10):1433-44. doi: 10.1515/bchm2.1979.360.2.1433.
7
[Medical genetics - preventive medicine of the future].[医学遗传学——未来的预防医学]
Srp Arh Celok Lek. 1977 Sep;105(9):783-6.
8
Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives.中性粒细胞与淋巴细胞比值与 COPD 的临床结局：最新证据与未来展望。
Eur Respir Rev. 2018 Feb 7;27(147). doi: 10.1183/16000617.0113-2017. Print 2018 Mar 31.
9
Preventive medicine 2000: changing contexts and opportunities.2000年的预防医学：不断变化的背景与机遇。
Acad Med. 2000 Jul;75(7 Suppl):S22-7. doi: 10.1097/00001888-200007001-00004.
10
[Preventive clinical medicine: the future of prevention].[预防临床医学：预防的未来]
Med Clin (Barc). 1994;102 Suppl 1:5-12.
本文引用的文献
1
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count.基于年龄、绝对中性粒细胞计数和绝对淋巴细胞计数的全球适用的原发性血小板增多症“三重 A”风险模型。
Am J Hematol. 2023 Dec;98(12):1829-1837. doi: 10.1002/ajh.27079. Epub 2023 Sep 4.
2
Asymptomatic SARS-CoV-2 Infection by Age: A Global Systematic Review and Meta-analysis.无症状 SARS-CoV-2 感染的年龄分布：一项全球系统综述和荟萃分析。
Pediatr Infect Dis J. 2023 Mar 1;42(3):232-239. doi: 10.1097/INF.0000000000003791. Epub 2022 Dec 1.
3
Red Cell Distribution Width and Absolute Lymphocyte Count Associate With Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis.红细胞分布宽度和绝对淋巴细胞计数与类风湿关节炎炎症标志物及随后的死亡率相关。
J Rheumatol. 2023 Feb;50(2):166-174. doi: 10.3899/jrheum.211411. Epub 2022 Nov 1.
4
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?遗传学是否有助于预测银屑病关节炎中 TNF 抑制剂的反应？
Pharmacogenomics J. 2023 Jan;23(1):1-7. doi: 10.1038/s41397-022-00290-8. Epub 2022 Oct 15.
5
Multivitamins and Supplements-Benign Prevention or Potentially Harmful Distraction?多种维生素与补充剂——良性预防还是潜在有害的干扰？
JAMA. 2022 Jun 21;327(23):2294-2295. doi: 10.1001/jama.2022.9167.
6
Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer.外周血淋巴细胞计数作为免疫检查点抑制剂治疗非小细胞肺癌患者疗效的替代标志物。
Sci Rep. 2022 Jan 12;12(1):626. doi: 10.1038/s41598-021-04630-9.
7
Lymphopenia Caused by Virus Infections and the Mechanisms Beyond.病毒感染引起的淋巴细胞减少症及其机制。
Viruses. 2021 Sep 20;13(9):1876. doi: 10.3390/v13091876.
8
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.预处理中性粒细胞与淋巴细胞比值和突变负担作为免疫检查点抑制剂肿瘤反应的生物标志物。
Nat Commun. 2021 Feb 1;12(1):729. doi: 10.1038/s41467-021-20935-9.
9
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.免疫检查点阻断在高突变实验性脑胶质瘤中的反应异质性。
Nat Commun. 2020 Feb 18;11(1):931. doi: 10.1038/s41467-020-14642-0.
10
Incidental lymphopenia and mortality: a prospective cohort study.偶然发现的淋巴细胞减少症与死亡率：一项前瞻性队列研究。
CMAJ. 2020 Jan 13;192(2):E25-E33. doi: 10.1503/cmaj.191024.
Zotero 插件